SORA, as a multi-receptor tyrosine kinase inhibitor that can inhibit the proliferation of multiple tumor cells and promote cell apoptosis, is commonly used for the treatment of hepatocellular carcinoma clinically (Keating, 2017). This evidence concerns the gene NTRK1 and neoplasm.